To further explore the potential function of DNA-PK-i in cancer treatment, we treated BRCA1-deficient UWB1 ovarian cancer cells with combination of low dose DNA-PK-i (M3814) with Pol I-i (BMH-21). This evidence concerns the gene BRCA1 and ovarian cancer.